Zhejiang Hisoar Pharmaceutical Hits Day Low Amid Price Pressure at CNY 7.49

Zhejiang Hisoar Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 7.48% on February 24, 2026. The stock reached an intraday low of CNY 7.49, reflecting a challenging trading environment for the company. In terms of performance metrics, Zhejiang Hisoar has shown mixed results over various time frames. While the stock has gained 2.13% over the past week and 7.72% over the last month, it has underperformed in the longer term, with a 5-year annual net sales growth rate of -6.39% and an operating profit decline of 180.98%. The company's market capitalization stands at CNY 11,906 million, categorizing it as a large-cap entity within the pharmaceuticals and biotechnology sector. However, it faces challenges such as a low return on capital employed of 2.16% and a debt-equity ratio of 0.01, indicating a conservative capital structure. Overall, the stock's performance today highlights ongoing concerns regarding its profitability and market position, as it continues to navigate a competitive landscape.